{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Omicron variant",
      "SARS-CoV-2",
      "bivalent mRNA vaccine",
      "neutralizing antibody"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "37632098",
  "DateCompleted": {
    "Year": "2023",
    "Month": "08",
    "Day": "28"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "09",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2023",
        "Month": "08",
        "Day": "17"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "1756",
      "10.3390/v15081756"
    ],
    "Journal": {
      "ISSN": "1999-4915",
      "JournalIssue": {
        "Volume": "15",
        "Issue": "8",
        "PubDate": {
          "Year": "2023",
          "Month": "Aug",
          "Day": "17"
        }
      },
      "Title": "Viruses",
      "ISOAbbreviation": "Viruses"
    },
    "ArticleTitle": "Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection.",
    "Abstract": {
      "AbstractText": [
        "In this study, we evaluated the effectiveness of the bivalent mRNA COVID-19 vaccines against the Omicron variant in individuals with or without prior SARS-CoV-2 infection history. We assessed the SARS-CoV-2-specific neutralizing antibody in serum samples by surrogate virus neutralizing assay (sVNT) and determined the serum's neutralizing capacity against the Omicron BA.5 by a plaque reduction neutralizing test (PRNT50). The results of the sVNT assay demonstrate a higher percentage of inhibition of the serum samples from the infected group than from the uninfected group (<i>p</i> = 0.01) before the bivalent vaccination but a similarly high percentage of inhibition after the vaccination. Furthermore, the results of the PRNT50 assay demonstrate a higher neutralizing capacity of the serum samples against Omicron BA.5 in the infected group compared to the uninfected group, both before and after the bivalent vaccine administration (<i>p</i> < 0.01 and <i>p</i> = 0.02 for samples collected before and after the bivalent vaccination, respectively). A higher neutralizing capacity of the serum samples against BA.5 following bivalent vaccination compared to those before vaccination suggests the efficacy of bivalent mRNA COVID-19 vaccines in triggering an immune response against the Omicron variant, particularly BA.5, regardless of infection history."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Gyeongsang Institute of Health Sciences, Gyeongsang National University, Jinju 52727, Republic of Korea."
          }
        ],
        "LastName": "Widyasari",
        "ForeName": "Kristin",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Gyeongnam Center for Infectious Disease Control and Prevention, Changwon 51154, Republic of Korea."
          }
        ],
        "LastName": "Jang",
        "ForeName": "Jieun",
        "Initials": "J"
      },
      {
        "Identifier": [
          "0000-0002-5387-6458"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Bionanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejon 34141, Republic of Korea."
          },
          {
            "Identifier": [],
            "Affiliation": "School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea."
          }
        ],
        "LastName": "Kang",
        "ForeName": "Taejoon",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Gyeongsang Institute of Health Sciences, Gyeongsang National University, Jinju 52727, Republic of Korea."
          },
          {
            "Identifier": [],
            "Affiliation": "Gyeongnam Center for Infectious Disease Control and Prevention, Changwon 51154, Republic of Korea."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Laboratory Medicine, College of Medicine Gyeongsang National University, Jinju 52727, Republic of Korea."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Laboratory Medicine, Gyeongsang National University Changwon Hospital, Changwon 51472, Republic of Korea."
          }
        ],
        "LastName": "Kim",
        "ForeName": "Sunjoo",
        "Initials": "S"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Viruses",
    "NlmUniqueID": "101509722",
    "ISSNLinking": "1999-4915"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Messenger"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [],
      "DescriptorName": "RNA, Messenger"
    }
  ],
  "CoiStatement": "The authors declare no conflict of interest."
}